Making mental health predictions based on clinical presentation has major limitations.
Dr. Roger McIntyre suggests that the clinical relevance of cognitive dysfunction for any individual patient can only be adjudicated on a case-by-case basis.
Neuroimaging studies have shown several neurophysiological substrates for depression: An overview by Theodore Henderson, MD, PhD.
Patients commonly report inter-episodic cognitive complaints during the "remitted" phases of depression that negatively affect their ability to engage in more cognitively demanding activities.
Questions remain as to whether botanically-derived marijuana offers clinical benefit over pharmaceutical-grade THC, its active ingredient.
Early adherence is an especially problematic, significant and modifiable barrier to quality care for depression.
Researchers examined whether the risk of relapse or time to relapse was related to type of anxiety disorder, duration of previous treatment, and other factors.
Augmentation therapy for treatment-resistant major depressive disorder includes multiple options with different strengths and limitations.
Scores for both anxiety and depression are associated with low BMD.
In young adults, MDD, GAD, and SSRI use is associated with bone metabolism.
Psychiatry Advisor Articles
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Duration of Untreated Depression Predicts Depression Severity
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Bipolar Depression Benefits From Midday Bright Light Therapy
- Buprenorphine, Methadone Combined With CNS Depressants May Lead to SAEs